Piper Sandler downgraded Supernus Pharmaceuticals Inc SUPN, saying that the anticipated surge in Qelbree prescriptions during the back-to-school season has not materialized as expected.“That has us rethinking our assumptions regarding the longer-term (LT) sales/volume growth trajectory of the product,” the analyst adds.Qelbree (viloxazine) is indicated to treat attention deficit hyperactivity disorder in children and adults.In the second quarter of 2024, net sales of Qelbree increased 92% year over year to ...